Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT05467046
Other study ID # ICBE-S-000319
Secondary ID
Status Completed
Phase
First received
Last updated
Start date August 3, 2022
Est. completion date December 7, 2023

Study information

Verified date April 2024
Source Philips Electronics Nederland B.V. acting through Philips CTO organization
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Atopic Dermatitis (AD), otherwise known as (atopic) eczema, is a chronic relapsing inflammatory skin disease. For difficult-to-treat AD, treatment options are limited. A better understanding of the underlying immunological cause, led to development of new, targeted therapies. For evaluating effectiveness and making treatment decisions for these new therapies, only 2 subjective methods exist: 1. clinical scores (AD-severity scored by a physician using structured scoring system), 2. questionnaires (completed by AD-patients). Therefore, an objective AD-severity assessment method might provide benefits for clinical practice. In this study, it is evaluated whether scratching and sleep parameters, obtained with a smartwatch worn by AD-patients, provide added value for clinical practice in dermatology. The usability of this smartwatch system is evaluated by AD-patients.


Description:

The study consists of two consecutive parts. In part 1, 30 AD-patient will be asked to wear a smartwatch during nighttime and to complete questionnaires regarding the usability of the smartwatch system. In part 2, a focus group with dermatology Health Care Practitioners (HCPs) will take place. In this focus group, the HCPs will evaluate whether the scratching and sleep parameters obtained from the smartwatches worn by the AD-patients in part 1, provide added value for clinical practice in dermatology. The primary objective is to collect insights in whether objectification of scratching and sleep in AD-patients during the night provides added value for clinical practice in dermatology. The secondary objective is to collect insights into the requirements of AD-patients and dermatology HCPs for a smartwatch system to be acceptable for use in the dermatology clinical practice.


Recruitment information / eligibility

Status Completed
Enrollment 16
Est. completion date December 7, 2023
Est. primary completion date September 30, 2023
Accepts healthy volunteers No
Gender All
Age group 18 Years to 65 Years
Eligibility For Atopic Dermatitis patients the eligibility criteria are: Inclusion Criteria: - Patient has signed informed consent for the BioDay registry and is enrolled in the BioDay registry. - Patient has a diagnosis of moderate to severe Atopic Dermatitis, and therefore will be treated with advanced systemic treatment in daily practice according to the Dutch AD guideline (after treatment failure of at least 1 oral immunosuppressive drug or a contra-indication for oral immunosuppressive drugs). - Patient has no concomitant immunosuppressive therapy at baseline - Age between 18 and 65 years old (18 years = Age = 65 years). - Intact skin at both wrists (definition of intact skin: Skin in which there are no breaks, scrapes, cuts, or abnormal openings that allow pathogens to enter). - Willing and able to provide written informed consent and participate in study procedures. - Able to understand, read and write Dutch. Exclusion Criteria: - Unable to understand instructions - Expected participation of less than 5 weeks - Travelling or holiday, for 1 night or more, outside the Netherlands during participation in the study. - Eczema lesions on one or both wrists at study recruitment - Patients with neurological disease (e.g., Parkinson's Disease) or physical disability affecting one or both hands, wrist and/or arms. - Irregular or affected sleep/wake pattern due to causes other than AD. (For example: medical conditions like sleep-apnea or primary insomnia, concomitant medication affecting sleep, alternating shift workers or AD-patients with young infants.) - Having a tattoo on the upper side of one or both wrists. (Tattoos in the wrist area can cause inaccurate measurements.) - Institutionalized patients (e.g., care home residents) - Prisoners (general inmates of prisons or other state institutions) - Philips research employees - Study site employees or any other research team member involved directly or indirectly in the conduct of the clinical study - Cognitively impaired (diagnosis of cognitive impairment in medical file) - Pregnant persons will not be considered for this study (during pregnancy, the treatment with advanced systemic treatment is not always possible) - If a patient is not allowed to visit the hospital due to the prevailing COVID-19 restrictions. (If COVID-19 restrictions indicate that it is not allowed to visit the hospital for example when having a positive COVID-19 test, then the patient cannot be included in the study, because it cannot comply with the BioDay study protocol, and thereby indirectly also not with the AD-study protocol). For dermatology HCPs the eligibility criteria are: Inclusion criteria - HCP is allowed to treat AD-patients - HCP is (trainee) dermatologist, (trainee) physician, (trainee) research-physician, (trainee) nurse practitioner, (trainee) physician assistant or similar, working in the field of dermatology - HCP has (digitally) signed consent form for the focus group - HCP works in a hospital that is a member of the BioDay consortium. Exclusion criteria - Unable or unwilling to attend focus group - Philips Research employees

Study Design


Related Conditions & MeSH terms


Intervention

Device:
Smartwatch system
The Atopic Dermatitis patient cohort is exposed to using a smartwatch system for 5 weeks.

Locations

Country Name City State
Netherlands University of Utrecht Utrecht

Sponsors (2)

Lead Sponsor Collaborator
Philips Electronics Nederland B.V. acting through Philips CTO organization UMC Utrecht

Country where clinical trial is conducted

Netherlands, 

Outcome

Type Measure Description Time frame Safety issue
Primary Feedback from dermatology HCPs on whether objectification of nighttime scratching and sleep in AD-patients provides added value for clinical practice in dermatology. 1 hour, after completion of study part 1
Secondary AD-Patient participant feedback via a questionnaire (usability schale) on the acceptability and usability of a wearable-solution for AD-patients. baseline, and after 5 weeks of participation
Secondary Nighttime sleep quality measured with a smartwatch. The following specific sleep quality parameters will be collected, amongst others, Total Sleep Time, Wake After Sleep Onset, Number of Awakenings baseline, and after 5 weeks of participation
Secondary Nighttime scratching parameters (e.g., number and duration of scratching periods) determined with a smartwatch. baseline, and after 5 weeks of participation
See also
  Status Clinical Trial Phase
Completed NCT05018806 - Proof of Concept Study of Rilzabrutinib in Adult Patients With Moderate-to-severe Atopic Dermatitis Phase 2
Completed NCT04090229 - A Multi-center, Randomized, Double-blind, Placebo-controlled, Multiple Ascending Dose Study of the Safety, Tolerability, and Pharmacokinetics of Subcutaneously Delivered ASLAN004 in Adults With Moderate-Severe Atopic Dermatitis Phase 1
Terminated NCT03847389 - Clobetasol Topical Oil for Children With Moderate to Severe Atopic Dermatitis Phase 1/Phase 2
Active, not recruiting NCT05388760 - Tralokinumab Monotherapy for Children With Moderate-to-severe Atopic Dermatitis - TRAPEDS 1 (TRAlokinumab PEDiatric Trial no. 1) Phase 2
Completed NCT05530707 - Evaluation of Acceptability, Skin Barrier Restoration and Balance of Atopic Skin Using Moisturizer N/A
Completed NCT02595073 - Clinical Study to Evaluate the Efficacy and Safety of Desoximetasone (DSXS) With Atopic Dermatitis Phase 3
Recruiting NCT05509023 - Evaluating Safety and Efficacy of ADX-914 in Patients With Moderate to Severe Atopic Dermatitis (SIGNAL-AD) Phase 2
Recruiting NCT05048056 - Phase 2 Study of Efficacy and Safety of AK120, in Subjects With Moderate-to-Severe Atopic Dermatitis Phase 2
Completed NCT04598269 - Study of ATI-1777 in Adult Patients With Moderate or Severe Atopic Dermatitis Phase 2
Recruiting NCT03936335 - An Observational Retrospective Cohort Study Being Conducted in Women With Atopic Dermatitis (AD)
Withdrawn NCT03089476 - Evaluating Skin Barrier Dysfunction in Infants at High Risk of Atopy N/A
Recruiting NCT05029895 - A Study to Evaluate Adverse Events and Change in Disease State of Oral Upadacitinib in Adolescent Participants Ages 12 to <18 Years Old Diagnosed With Atopic Dermatitis (AD)
Terminated NCT03654755 - Study to Evaluate Long-Term Safety of ASN002 in Subjects With Moderate to Severe Atopic Dermatitis Phase 2
Completed NCT04556461 - Effects of Tralokinumab Treatment of Atopic Dermatitis on Skin Barrier Function Phase 2
Recruiting NCT04818138 - BROadband vs Narrowband photoTherapy for Eczema Trial Nested in the CACTI Cohort N/A
Completed NCT03719742 - A Clinical Study to Evaluate the Safety and Efficacy of a Baby Cleanser and a Moisturizer N/A
Completed NCT05375955 - A Study to Learn About The Study Medicine (PF-07038124) In Patients With Mild To Moderate Atopic Dermatitis Or Mild To Severe Plaque Psoriasis. Phase 2
Completed NCT03441568 - In-home Use Test of the New Modified Diprobase Formulation to Assess the Safety and Tolerability in Infants and Children Under Physician's Control N/A
Recruiting NCT06366932 - Optimization of Atopic Dermatitis Treatment That Requires Second-line Systemic Therapy Through Predictive Models Phase 4
Completed NCT03304470 - A Study to Evaluate the Safety and Efficacy of ATx201 in Subjects With Moderate Atopic Dermatitis Phase 2